Reviewing Myovant Sciences Ltd. (MYOV)’s and Altimmune Inc. (NASDAQ:ALT)’s results

We are comparing Myovant Sciences Ltd. (NYSE:MYOV) and Altimmune Inc. (NASDAQ:ALT) on their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myovant Sciences Ltd. 16 0.00 36.73M -3.80 0.00
Altimmune Inc. 2 0.00 11.69M -4.33 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Myovant Sciences Ltd. and Altimmune Inc.


Table 2 provides us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Myovant Sciences Ltd. 232,174,462.71% -768.5% -140.4%
Altimmune Inc. 635,636,996.36% -79.1% -70.7%


The Current Ratio of Myovant Sciences Ltd. is 2.8 while its Quick Ratio stands at 2.8. The Current Ratio of rival Altimmune Inc. is 16.9 and its Quick Ratio is has 16.9. Altimmune Inc. is better equipped to clear short and long-term obligations than Myovant Sciences Ltd.

Analyst Ratings

Myovant Sciences Ltd. and Altimmune Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Myovant Sciences Ltd. 0 0 2 3.00
Altimmune Inc. 0 0 0 0.00

Myovant Sciences Ltd. has a 66.06% upside potential and an average target price of $23.

Institutional and Insider Ownership

Roughly 41.4% of Myovant Sciences Ltd. shares are held by institutional investors while 7.3% of Altimmune Inc. are owned by institutional investors. About 49.9% of Myovant Sciences Ltd.’s share are held by insiders. On the other hand, insiders held about 2.1% of Altimmune Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Myovant Sciences Ltd. -6.74% 195.03% 139.34% 80.54% -10.7% 1.22%
Altimmune Inc. 3.3% 0.54% -11.74% -19.66% -41.25% -8.74%

For the past year Myovant Sciences Ltd. has 1.22% stronger performance while Altimmune Inc. has -8.74% weaker performance.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womenÂ’s health and endocrine diseases. The companyÂ’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, designs and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. Its preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others. The company was formerly known as Vaxin Inc. Altimmune, Inc. was founded in 1997 and is based in Gaithersburg, Maryland.